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Although cord blood transplantation has significantly extended the lifespan of mucopolysaccharidosis 
type 1 (MPS1) patients, over 95% manifest cornea clouding with about 50% progressing to blindness. 
As corneal transplants are met with high rejection rates in MPS1 children, there remains no treatment 
to prevent blindness or restore vision in MPS1 children. Since MPS1 is caused by mutations in idua, 
which encodes alpha-L-iduronidase, a gene addition strategy to prevent, and potentially reverse, 
MPS1-associated corneal blindness was investigated. Initially, a codon optimized idua cDNA expression 
cassette (opt-IDUA) was validated for IDUA production and function following adeno-associated virus 
(AAV) vector transduction of MPS1 patient fibroblasts. Then, an AAV serotype evaluation in human 
cornea explants identified an AAV8 and 9 chimeric capsid (8G9) as most efficient for transduction. 
AAV8G9-opt-IDUA administered to human corneas via intrastromal injection demonstrated 
widespread transduction, which included cells that naturally produce IDUA, and resulted in a >10-fold 
supraphysiological increase in IDUA activity. No significant apoptosis related to AAV vectors or IDUA 
was observed under any conditions in both human corneas and MPS1 patient fibroblasts. The collective 
preclinical data demonstrate safe and efficient IDUA delivery to human corneas, which may prevent and 
potentially reverse MPS1-associated cornea blindness.
Mucopolysaccharidosis1 (MPS1) is an autosomal recessive lysosomal storage disorder caused by null or nonsense 
mutations in the gene encoding alpha-L-iduronidase (IDUA), a ubiquitous intracellular and secreted enzyme that 
breaks down glycosaminoglycans (GAGs). In the absence of functional IDUA, GAGs accumulate in lysosomes 
and disrupt the normal intracellular trafficking of lipids, sugars, and proteins causing multisystem end organ 
damage. The incidence of MPS1 is approximately 1 in 100,000 and the disease is characterized by hepatosple-
nomegaly, cardiac insufficiency, bone and joint deformities, dwarfism, mental retardation and serious nervous 
system problems, which commonly result in death by 10 years of age. Additional symptoms include hearing loss, 
joint stiffness, and clouding of the cornea which results in loss of vision1.
Current MPS1 treatments include IDUA enzyme replacement therapy (ERT) (Aldurazyme) via intravenous 
injections, which has proven useful in reducing hepatosplenomegaly, and in improving myocardiac function, 
pulmonary symptoms and motility in MPS1 patients with mild disease. A more promising treatment relies on 
allogeneic hematopoietic stem cell transplantation (HSCT) which has been used for the past 2–3 decades in MPS1 
patients. HSCT has proven successful at improving cognitive function, reducing hepatosplenomegaly, prevent-
ing ischemic cardiac disease and prolonging the patient’s lifespan, in some cases by decades. Clinical outcomes 
are best when myeloablative chemotherapy and cord blood donors are utilized, as it increases the extent of sus-
tained donor chimerism. A third MPS1 treatment approach that is still under preclinical evaluation relies on an 
adeno-associated virus (AAV) IDUA gene addition strategy. Central nervous system (CNS) targeted AAV-IDUA 
gene therapy has been explored in murine, feline, and canine MPS1 models following administration via several 
routes including the carotid artery, intraparenchymal, intraventricular and intrathecal2–4. These gene therapy 
studies independently report histological, biochemical, and in particular cognitive improvements while, impor-
tantly, IDUA-related toxicity was not observed. However, ERT, HSCT and AAV CNS-targeted or systemic gene 
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therapy exhibit a common deficiency; the inability to correct MPS1-associated maladies in privileged compart-
ments including the joint and eye.
Regarding the ocular abnormalities, approximately 90% of MPS1 children lose vision due to corneal cloud-
ing, which has been attributed to the abnormal presence of vacuolated stroma cells5. Detailed analyses of MPS1 
human corneas demonstrated an accumulation of chondroitin and dermatan sulphate GAGs, which alter the 
uniform distribution, organization, and size of collagen fibrils6,7. Cornea transplantation in MPS1 children has 
been used to address the corneal blindness, however the high rejection rate has, in recent years, discouraged this 
treatment as standard practice. On the contrary, isolated reports using HSCT have demonstrated the capacity to 
stabilize, improve, and in some cases restore corneal clarity7–12. These data strongly support our hypothesis that 
cornea abnormalities can be prevented or reversed in the presence of IDUA8.
Cornea targeted AAV gene therapy has been investigated in animal models primarily following 2 routes of 
administration; topical applications in wound healing assays and direct injection to the corneal stroma. Regarding 
topical applications, AAV serotype 9 (AAV9) was reported most efficient for stromal transduction, however, 
this was nearly entirely localized to the epithelial/stromal boundary13. Regarding AAV gene delivery following 
intrastromal injection into human cornea explants, it was observed that AAV8 was more efficient than AAV2 
or AAV1 for stromal transduction, which encompassed multiple cell types including CD34 + keratocytes and 
macrophages14. Importantly, both of these routes of drug administration observed no deleterious consequences 
related to the AAV vector13–15.
The purpose of the present study is to explore AAV-mediated IDUA delivery as an effective treatment for 
MPS1 cornea clouding. Towards this end, we engineered an AAV vector cassette that efficiently restores IDUA 
to MPS1 patient fibroblasts in a dose-dependent manner. Normal, and supraphysiological, IDUA activity was 
demonstrated in both cellular lysates and in culture supernatants. Then, as MPS1 corneal disease has been attrib-
uted to stroma abnormalities5, the AAV serotypes reported most efficient for stromal transduction were evalu-
ated in human corneas. The results demonstrate efficient transduction (AAV9 > AAV8), however, an AAV8/9 
chimeric (8G9) capsid performed significantly better than either parental serotype. Using AAV8G9, IDUA was 
over-produced in the human corneal stroma with widespread distribution in multiple cell types, which included 
cells that naturally produce IDUA. Functional assays in human corneas demonstrated a 10-fold elevation of IDUA 
activity seven days post-injection without any indications of toxicity. Given the popularity of AAV gene therapy in 
ocular clinical trials, the soluble nature of IDUA, and the potential for compassionate use of AAV-IDUA in MPS1 
children, our preclinical data herein provides encouraging results for a potential treatment of MPS1-associated 
corneal clouding.
Results
To develop an AAV IDUA expression cassette, the human idua cDNA (NM_000203) was codon optimized 
for human production (opt-IDUA) and situated between the CMV promoter and the SV40 poly-adenylation 
sequence in an AAV inverted terminal repeat serotype 2 plasmid context (Fig. 1A). Production of IDUA protein 
by the pTR-CMV-opt-IDUA plasmid was confirmed, after performing transfection and Western Blot experi-
ments with human embryonic kidney 293 cells and MPS1 patient fibroblasts (Fig. S1A,B). Additionally, IDUA 
protein levels from the codon optimized open reading frame were similar to that generated by wild type IDUA 
cDNA in both 293 cells and MPS1 patient fibroblasts (Fig. S1).
AAV2-opt-IDUA vectors were prepared as described16 and used for characterization in MPS1 patient derived 
fibroblasts. Immortalized normal human fibroblasts (NHF) served as the control cell line17. In dose escalation 
experiments, AAV2-opt-IDUA transduction of MPS1 fibroblasts resulted in increasing levels of IDUA restora-
tion, in both cellular lysates and in the culture supernatant (Fig. 1B). In fact, as resting levels of IDUA in NHF are 
relatively low, a dose of 5,000 viral genomes/cell resulted in already supraphysiological levels in both cell lysates 
and in culture supernatants (Fig. 1B). Consistently, IDUA function was restored and elevated in transduced MPS1 
patient fibroblasts with a 10-fold and 30-fold increases in cellular lysate and supernatant, respectively, at the high-
est investigated dose (Fig. 1C,D). Despite IDUA overproduction following AAV vector transduction, no toxicity 
was observed in patient fibroblasts at any dose using a dye exclusion assay (Fig. S2). Importantly, these results 
demonstrate the functionality and safety of AAV2-opt-IDUA in a MPS1 patient context.
An analysis of MPS1 patient corneas attributed stromal abnormalities as the cause of the corneal opacity 
that results in vision loss5. Therefore, direct administration of AAV-opt-IDUA should restore IDUA activity in 
the corneal stroma compartment of MPS1 patients, hopefully preventing or reversing the MPS1 phenotype. 
Previous reports demonstrated the utility of both AAV814 and AAV913 for human keratocyte transduction, one 
of the most prevalent cell types present in the cornea. As such, these capsids, carrying a self-complementary (sc) 
AAV-CMV-GFP genome, were evaluated in normal human corneal explants, which remain viable for weeks 
post-mortem. Preliminary experiments demonstrated that a volume of 50μl injected into the stroma was toler-
ated with minimal tissue distension and a distribution across ≈ 50% of the adult cornea using the vector vehicle 
containing india ink (Fig. S3). Therefore, AAV serotypes 8 or 9 containing a GFP reporter gene were administered 
to human cornea stroma by injection (1e10 vg in 50 ul) and analyzed seven days later by Western blotting. Given 
the reports of both 8 and 9 for cornea transduction, an AAV8/9 chimeric capsid (8G9), containing the galactose 
receptor of AAV9 engrafted on the AAV8 capsid was also investigated in the same manner13,14. Western blotting 
suggested that AAV8G9-GFP resulted in greater transduction than either parent serotype (Fig. 2A). In order 
to quantify the degree of viral transduction of the different serotypes on the human corneas, we performed a 
quantitative ELISA GFP assay (Fig. 2B). Single stranded versions of the AAV serotypes 8, 9 and 8G9 carrying the 
CMV-GFP cassette were used for cornea infection for seven days. After that time, viral transduction was deter-
mined according to the amount of GFP expressed by the infected cells. Statistical analysis revealed that AAV8G9 
was able to infect the human cornea to a higher extent, compared to the transduction obtained by the parental 
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capsids AAV8 or AAV9; p ≤ 0.05 for both cases. This analysis was performed with a total of five human corneas 
of mixed gender.
In order to determine the biodistribution of single-strand AAV8G9-GFP transduction (final volume 50 μl), 
GFP immunofluorescence was performed on human corneal cross sections. The results demonstrate a lateral 
spread of vector transduction across the cornea with penetration into the deeper stromal layers, including some 
endothelial cell transduction (Fig. 2C). Co-staining with CD34, a marker of keratocytes, with alpha-smooth mus-
cle actin (alpha-SM), indicative of differentiated keratocytes, and with F4/80, a macrophage marker, demon-
strated the corneal cell promiscuity for the AAV8G9 capsid (Fig. 2D).
Following confirmation that the AAV8G9 capsid was the most efficient for corneal stroma transduction, we 
determined if the cell types transduced by AAV8G9 naturally produce IDUA. To do this, dual staining for the cell 
type marker and the IDUA protein was performed in normal untreated human corneas. The results indicate that 
all of the confirmed corneal cell types transduced by AAV8G9 naturally produce IDUA (Fig. 3A).
Next, AAV8G9-opt-IDUA preclinical vector preparations were produced by the UNC Vector Core and eval-
uated in normal human corneas ex vivo. For these experiments, injection of single-strand AAV8G9-GFP was 
evaluated and PBS served as the negative control. Seven days post-injection (1e10 vg in 50 μl), total protein was 
recovered and IDUA abundance was investigated by Western blotting. In whole corneal lysates, it was observed 
that the resting levels of IDUA are relatively low and that vector-derived IDUA, both the precursor and cleaved 
forms, was readily detected (Fig. 3B). Consistently, a 10-fold elevation of IDUA activity was observed in the 
AAV8G9-opt-IDUA injected corneas when compared to the normal levels found in human corneas (Fig. 3C).
By immunofluorescence staining and detection on human cornea cross sections, the resting levels and distri-
bution of IDUA were determined (Fig. 4). As MPS1 patient corneas are rare, staining under the same conditions 
but without the IDUA primary antibody served as the negative control. The results demonstrate relatively low 
levels of IDUA within the corneal stroma that were also present in the corneal epithelia and to a lesser extent, in 
the endothelial cell layer (Fig. 4). IDUA staining was also performed on human cornea cross sections that were 
injected with AAV8G9-opt-IDUA. The results correlate to those of the IDUA Western blot and the functional 
Figure 1. Restoration of IDUA activity in MPS1 patient fibroblasts by AAV gene therapy. (A) Schematic 
diagram of the AAV-IDUA optimized vector construct. (B) Cell lysates (Left panel) and supernatants (Right 
panel) from AAV2 infected and not-infected fibroblasts, normal human fibroblasts (NHF) or MPS1 fibroblasts, 
were analyzed for IDUA protein expression. Detection of β -actin was performed as a loading control of total 
protein in cell lysates. All the experiments were performed in triplicate. (C) Functional activity of IDUA 
protein was obtained for cell lysates and supernatants from AAV2 infected and not-infected fibroblasts, NHF 
or MPS1 fibroblasts. For cell lysates, the nmoles of 4-MU were normalized to one hour reaction and mg total 
protein. For cell supernatants, the nmoles of 5-MU were normalized to 10 μl of the sample. All the experiments 
were performed in triplicate. 4-MU, 4-methylumbelliferone; CMV, cytomegalovirus promoter; ITR, inverted 
terminal repeats; GFP, Green fluorescence protein.
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assay (Fig. 3) in that there is an approximate 5–10 fold increase in IDUA in normal human corneas treated with 
AAV8G9-opt-IDUA compared to the resting level in human corneas (Fig. 4). Furthermore, similar to the results 
observed with AAV8G9-GFP, vector derived IDUA appeared well distributed (Figs. 2C and 4).
Considering restoration of IDUA to the MPS1 patient cornea, it is critical to determine any vector or IDUA 
related toxicity. Due to unavailability of a small animal model for MPS1 that develops cornea clouding, we 
performed apoptosis experiments in normal human corneas following AAV8G9-GFP or AAV8G9-opt-IDUA 
stromal injection (1e10 vg). Tunel staining, which detects fragmented DNA indicative of cellular apoptosis, 
was performed on day 7 post-injection. Although the nuclease-treated positive control samples demonstrated 
extensive Tunel staining, the staining of corneas in which IDUA abundance/function were significantly elevated 
did not show a significant difference to the ones non-injected or injected with AAV8G9-GFP (Fig. 5). These 
results are consistent with those obtained using MPS1 patient fibroblasts and collectively suggest the safety of 
AAV8G9-opt-IDUA gene therapy in MPS1 patient corneas. However, a complete toxicity study should be per-
formed in an in vivo MPS1 model, where immune responses and/or liver toxicity could be evidenced.
Figure 2. AAV capsid serotype evaluation in human cornea. (A) Human corneas were injected with a 
self-complementary CMV-GFP cassette encapsidated in AAV serotypes 8, 9, or the 8/9 chimeric 8G9. Seven 
days later Western blot was used to detect GFP. PBS corresponds to a human cornea injected with only PBS 
(vehicle control). Detection of β -actin was performed as a loading control. (B) Human cornea pieces were 
incubated with 1 × 1010 viral genomes of each serotype: 8, 9, or the chimeric 8G9, but as single stranded 
viruses. Seven days following viral infection, the tissues were collected and the protein lysates were obtained 
for quantification of GFP. Human corneas incubated with the medium but replacing the viral addition for PBS 
were used as negative controls (PBS). Absorbance measurements at 450nm were normalized to total protein 
concentration. (*corresponds to p ≤ 0.05 when performing T-tests comparing normalized absorbance 450nm 
values for AAV8G9 with AAV8 or AAV9; N = 5). (C) Single-strand AAV8G9-CMV-GFP was injected into the 
stroma of human corneas and harvested for histology 7 days later. Left- Immunofluorescence image showing 
the distribution of recombinant AAV8G9-GFP transduction across a human cornea section. Human corneas 
injected with PBS served as the negative control. Images were obtained with 10× objective and assembled by 
stitch processing. The scale bar is equal to 2000 μm. Right- Different areas of the same stained human cornea 
taken with 20× objective. The scale bar is equal to 100 μm. Hoechst was used for nuclei counterstain. (D) A 
representative section of the corneas in (C) stained with GFP (green) and the indicated cell marker (red). The 
scale bar is equal to 10 μm. Hoechst was used for nuclei counterstain.
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Discussion
Hematopoietic stem cell transplantation, after myeloablative chemotherapy using allogeneic bone marrow or 
umbilical cord blood donors has been shown to extend life and improve its overall quality, particularly when 
performed in MPS1 children under 2 years of age18–22. Engrafted donor cells provide a source of systemic IDUA 
and, through engraftment of donor microglial cells, enzyme replacement in the brain. Transplanted children, sur-
viving 1–2 decades after HSCT with full donor chimerism, have normal blood IDUA levels with normal, to near 
normal, cognitive and cardiac functions. Later, and ongoing, manifestations of MPS1 after transplantation do 
occur and generally are limited to the joints, bones, and the eye, all of which are organs with lower profusion and 
lower delivery of donor-derived IDUA. As such, our preclinical corneal approach explored herein, was designed 
as a supplemental MPS1 therapy to address the shortcomings of stem cell transplantation and AAV gene therapy 
targeting the CNS.
As MPS1 patient corneas are rarely available, we initially investigated disease correction in MPS1 patient 
fibroblasts. The data demonstrate restoration of IDUA function using a low vector dose. This is, in part, due to 
the relatively low level of IDUA in normal fibroblasts which is presumably sufficient for normal cellular physiol-
ogy (Fig. 1). Consistently, the abundance of IDUA found in normal human corneas was also modest. In fact, in 
whole cornea lysates, IDUA abundance by Western blotting was not readily detected, however, tissue histology 
identified resting levels of IDUA in corneal epithelia, endothelia and the majority in multiple cell types found in 
the stroma (Figs 3 and 4). This evaluation of IDUA abundance and AAV-mediated restoration highlights a very 
important aspect to our corneal gene therapy approach: mainly that only a low amount of IDUA is necessary 
to restore WT IDUA function in the corneas of MPS1 children. This evidence is supported by studies with the 
MPS1 canine model, in which cornea clouding was significantly improved in presence of low levels of IDUA , 
meanwhile higher levels of IDUA did not provide further benefit23. In our experiments, our chosen AAV dose 
in the cornea explants (1e10 vg) was found to be excessive and resulted in a 10-fold supraphysiological elevation 
of IDUA function. However, even at this high IDUA level no apoptosis was detected (Figs 3–5). Given the ability 
of secreted IDUA to cross-correct neighboring cells, the low resting levels in normal human corneas, and the 
efficiency of AAV8G9-opt-IDUA for human cornea transduction, the data herein suggest that a low vector dose 
will result in normal levels of IDUA in MPS1 patient corneas. Furthermore, reported complications associated 
with a neutralizing antibody response to the IDUA transgene product (IDUA) are not anticipated as there are no 
antibodies in the human cornea24. However, at this point we are not able to predict the occurrence of any type of 
immune reaction or liver-associated toxicity.
Figure 3. Restoration of IDUA activity in human corneas by AAV8G9-opt-IDUA. (A) A representative 
section of a normal non-injected cornea stained with IDUA antibody (red) and a cell marker (green). Hoechst 
was used for nuclei counterstain. The scale bar is equal to 10 μm. (B) Western blot detecting IDUA amounts 
produced after injection of AAV8G9-opt-IDUA. Administration of AAV8G9-GFP served as a vector infection 
control. B-actin serves as a loading control. (C) Functional activity of IDUA protein obtained from human 
corneas 7 days post-injection of AAV8G9-opt-IDUA. AAV8G9-GFP served as the negative control. The nmoles 
of 4-MU were normalized to one hour reaction and mg total protein. PBS corresponds to a human cornea 
injected with only the vehicle control. The experiment was performed in triplicate.
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Given the collective data herein, restoring IDUA function in MPS1 corneas seems quite feasible. Furthermore, 
it appears that AAV8G9 elicits IDUA production in stromal cells that naturally produce IDUA, as well as in 
the endothelial layer (Fig. 4). Despite the ability to restore IDUA in the cornea, the question of whether or not 
restoration of IDUA in the cornea will reverse corneal clouding remains unanswered. However, several lines of 
evidence suggest that IDUA in the MPS1 cornea will reverse the corneal blindness7,23. In particular, the reduction 
of corneal opacity, but not complete correction, was reported in MPS1 patients receiving HSCT5. In that work it 
was hypothesized that the partial correction was due to restoration of IDUA in the corneal endothelium but not 
in the stroma. As our AAV-opt-IDUA strategy is capable of transducing both of these compartments (Fig. 4), the 
likelihood of reversing or preventing MPS1-associated corneal blindness, as a supplemental therapy to HSCT or 
AAV systemic gene delivery remains a viable possibility.
Materials and Methods
Production of AAV vectors. For cell culture experiments, a previously described triple transfection method 
was used to generate the vectors used herein25. This method used the pXR2 or pXR8G9 (manuscript submitted) 
plasmids, which all contain rep2 of AAV and individually the capsid genes of the indicated serotype. The plasmid 
containing the intended AAV genome was first constructed by substituting the egfp gene in pTR-CMV-eGFP 
with the codon optimized IDUA cDNA (provided by GenScript) at the AgeI and SalI sites (now called pTR-
CMV-opt-IDUA), or the wild type full-length hIDUA cDNA (kindly provided by Dr. Aronovich26) (now called 
pTR-CMV-WTIDUA). Following AAV production and cesium chloride gradient separation25, peak fractions were 
dialyzed against PBS, and titered by quantitative PCR (CMV_F CAA GTA CGC CCC CTA TTG AC, CMV_R 
AAG TCC CGT TGA TTT TGG TG) which was confirmed by Southern dot blot25. For the experiments in human 
explants, GMP grade vector preparations were provided by the UNC vector core.
Cell culture and vector transduction. Human embryonic kidney 293 cells, MPS1 patient fibroblasts, 
and normal human fibroblasts17 were maintained at 37 °C in a 5% CO2 atmosphere in Dulbecco’s modified 
Eagle’s medium (Sigma) supplemented with 10% fetal bovine serum and penicillin–streptomycin (100 U/ml). 
Transduction of cultured cells was performed in a 24 well plate in a fixed volume. For these experiments, vector 
was added to the wells at the indicated viral genome per cell dose and was not removed for the duration of the 
experiment.
Figure 4. Distribution of IDUA protein following AAV-8G9-opt-IDUA transduction. (A) Immunofluorescence 
image showing the distribution of IDUA protein across a human cornea section seven days post-injection of 
AAV8G9-opt-IDUA or PBS (vehicle). The images were obtained with 10× objective and assembled by stitch 
processing. The scale bar is equal to 2000 μm. Hoechst was used for nuclei counterstain. (B) Cross section of the 
same stained human corneas but taken with a 20× objective. The top figure corresponds to the negative control 
of staining, which was treated in the same manner as the other samples but without the primary antibody. 
Hoechst was used for nuclei counterstain. The scale bar is equal to 100 μm. The experiment was performed in 
duplicate.
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Human Cornea Experiments. All experimental protocols were approved by the University of North 
Carolina at Chapel Hill. Human corneas were provided by the miracles in sight tissue procurement bank. These 
unidentified post-mortem tissue experiments were performed in accordance with the human subjects research 
office of human research ethics at the University of North Carolina at Chapel Hill (IRB-14-1019). The corneas 
of both genders were maintained in the supplied opti-mem at 37 °C in a 5% CO2 atmosphere. Injections were 
performed with a 31 gauge insulin syringe. India ink was used as a dye to verify the injections. Corneas were then 
cultured for 7 days and analyzed as described in the text. For detection of GFP by Elisa, human corneas were 
trimmed into several pieces of similar size and each piece was incubated in a separate well in a certain condition.
Quantitative GFP detection by ELISA. Human cornea pieces were infected with 1 × 1010 viral genomes 
of each serotype: 8, 9, or the 8/9 chimeric 8G9 for seven days. Cell lysates were obtained by cutting each cornea 
into pieces and incubating the pieces with 200 μl M-PER® Mammalian Protein Extraction Reagent (Pierce, cat-
alog number: 78503) and 2 μl Halt™ Protease Inhibitor Cocktail for 10 minutes, followed by repeating freezing 
and thawing procedures. An aliquot of 100 μl of each lysate was incubated at 4 °C overnight with the anti-GFP 
antibody coated plate (Cell Biolabs, Inc, catalog number AKR-121). Following extensive washes, a second incuba-
tion with an anti-GFP antibody, but this time biotinylated, was performed for 2 hours at room temperature. Wells 
were washed and streptavidin-enzyme conjugate was added to each well. The reaction took place by adding the 
substrate for the enzyme and once the color was developed, the reaction was stopped and absorbance at 450 nm 
was measured.
Functional IDUA assay. Quantitative IDUA enzyme activities were measured as previously described27. 
Briefly, 10 μl of a supernatant or cell lysis solution, obtained the same way as for the detection of GFP by ELISA, 
were incubated with 50 μM 4-methylumbelliferyl alpha-L-iduronide made in 0.4 M sodium formate buffer, pH 
3.5, containing 0.2% Triton x-100 at 37C for 60 min in the dark. Reactions were stopped by adding 80 μl of 0.5 M 
NaOH/glycine buffer pH 10.3. The 96 well plates were centrifuged for 1 min 13000 rpm at 4C and supernantans 
were transfered to a black 96w plate, clear bottom with lid for measuring fluorescence at 450 nm, following excita-
tion at 365 nm. The amount of cleaved substrate was calculated from a standard curve, previously established 
Figure 5. No apoptosis following AAV8G9-opt-IDUA injection in human corneas. (A) Human corneas 
injected with PBS, AAV8G9-GFP, or AAV8G9-opt-IDUA were processed 7 days later for Tunel staining. 
Top, images taken at 10× . Bottom, images taken at 20× . As a positive control, human corneas injected with 
PBS where nuclease treated. The scale bar is equal to 100 μm. (B) Quantitation of pixel area for total staining 
performed in (A). A minimum of 7 areas per cornea for each treatment were counted using SigmaScan Pro 
software. No statistical difference between cytotoxicity for corneas injected with AAV8G9-GFP or AAV8G9-
opt-IDUA was observed (p > 0.05).
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with 4-methylumbelliferone and expressed as nmol/h/mg for enzyme activity in cell lysates, or nmol/h/10 μl for 
analysis of supernatants . The protein amount for each sample was determined with the BCA assay (Pierce™ BCA 
Protein Assay Kit, catalog number: 23225).
Tunel Assay. Apoptotic cells generated due to the cellular cytotoxicity during AAV infection of human cor-
nea explants were determined by deoxynucleotidyltransferase (TdT)-mediated dUTP-biotin nick end labeling 
with DAB. Tunel assay was performed with TACS2 TdT-Blue Label in situ apoptosis detection kit (Trevigen, 
Gaithersburg, Md.). Briefly, following deparaffinization and rehydration, the human cornea sections were 
digested for 20 min in proteinase K. Slides were washed with 1 × PBS and the endogenous peroxidase activity was 
quenched by incubating the tissues with 3% H2O2 solution in Methanol. After washing the slides with 1 × PBS, 
tissue sections were incubated with 1× TdT labeling buffer for 5 min. The labeling reaction consisting of incubat-
ing the cornea tissues with TdT enzyme, dNTPs with biotinylated dUTP, and 1 × manganese chloride in 1 × TdT 
labeling buffer for 1 h in a humidified chamber at 37C. The reaction was completed by incubating with 1 × TdT 
stop buffer. The fragmented DNA was visualized by treating the sections with streptavidin-conjugated horserad-
ish peroxidase and DAB solution.
Immunofluorescence Staining. Human cornea tissues were embedded in paraffin and sectioned at a 
thickness of 5 μm using a microtome. In order to stain the slide with immunofluorescence antibodies, sections 
were deparaffinized by incubating the slides in xylene for 5 min, two times total, followed by rehydration by 
immersing them sequentially in 100%, 95% and 70% ethanol solutions, 5 min each, and finally in water for 5 min. 
Before staining the sections, antigen retrieval procedure was performed in order to guarantee the exposure of 
epitopes, which were previously masked due to the paraffin embedding process. Specifically, slides were immerse 
into pre-heated antigen retrieval solution (Dako) at 98C for 7 min. Non-specific binding sites within the tis-
sues were then blocked by incubating the slides with 10% NGS, in 1× PBS for 1 hour at RT. Slides were washed 
twice for 5 minutes each with 2% NGS in 1× PBS. Sections were then incubated overnight at 4 °C with primary 
antibody diluted appropriately in a solution consisting of 2% NGS in 1× PBS. After incubation with primary 
antibody, slides were washed three times, for 5 minutes each, in order to remove non-specifically bound primary 
antibody. The washing solution contained 2% NGS in 1× PBS. An appropriate fluorescently-labeled secondary 
antibody (5 μg/ml) was then added to the slides diluted in 2% NGS in 1× PBS, and slides were incubated for 
1 hour at 4 °C. Finally, slides were washed twice with 2% NGS in 1× PBS three times, for five minutes each, fol-
lowed by a last wash with 1× PBS at 4 °C. A couple of drops of Hoechst (Molecular probes- Life technologies, 
H3569 Hoechst 33258, Pentahydrate-1 μg/mL) were added for 7 minutes to counterstain the nuclei within the 
section, followed by a wash with water. Slides were then coverslipped with Cytoseal 60 (Thermo Fisher Scientific 
(NYSE: TMO)).
Primary antibodies used for this study. For IDUA staining, Rabbit Polyclonal IDUA antibody (Biorbyt, 
catalog number: orb157615, dilution 1/50); for GFP staining, Chicken anti GFP antibody (Aves, catalog number: 
GFP-1020, dilution 1/100); for CD34 staining, mouse monoclonal antibody (clone: B-6) (Santa Cruz, sc-74499, 
dilution 1/100)), for α -Smooth Muscle Actin staining, mouse monoclonal antibody (R&D, clone #1A4, catalog 
number MAB1420, dilution 1/100), and for F4/80 marker staining, rat monoclonal antibody, (clone: BM8) (Santa 
Cruz, sc-52664, dilution 1/100). Secondary antibodies were the following: Alexa Fluor® 594 goat anti-rabbit 
IgG (A-11012) (Gibco – Invitrogen, Carlsbad, CA), Alexa Fluor® 594 goat anti-chicken IgG (A-11039) (Gibco – 
Invitrogen, Carlsbad, CA), Alexa Fluor® 594 goat anti-rat IgG (A-11006) (Gibco – Invitrogen, Carlsbad, CA) and 
Alexa Fluor® 488 goat anti-mouse IgG (A-11001) (Gibco – Invitrogen, Carlsbad, CA). Images from each slide 
were taken using a Zeiss LSM 780 Confocal Microscope with a 40× objective (Olympus, Tokyo, Japan). Images 
that comprised the complete human cornea were taken with 10× objective, the title function and then stitched. 
Images were then processed using Adobe Photoshop. Sections from each tissue were stained with secondary 
antibody alone as negative control staining in all experiments.
MPS1 Cell Transfection and Western Blot. MPS1 fibroblast patient cells were plated onto a 24 well plate 
at 20,000 cells per well. After 24 hours, nine wells were transfected for each treatment adding a mix 1ug of plasmid 
DNA, 3μl of PEI and 60 μl of DMEM to each well. 24 hours after transfection, 40μl of supernatant were collected 
from each well and 3 wells were combined to form each sample. 40 μl of DMEM were added to each well to 
maintain the same volume for later supernatant collections. 48 hours after transfection, total supernatant was col-
lected combining 3 wells to again form triplicates. At that time total cell protein was harvested by adding 70 μl of 
Mammalian Protein extraction Reagent (Thermo Scientific Cat: 78501), per well and following reagent protocol.
For Western blot, Protein lysate was added to a solution of 5% beta-mercapto-ethanol in 4× Nupage sample 
buffer. The resulting solution was boiled for 10 minutes and chilled on ice for 10 minutes and then run in a 10% 
Bis-tris pre-cast gel. Gel was run in 1× MOPS running buffer, and transferred to a nitrocellulose membrane. The 
membrane was blocked with 5% milk in ddH20, and probed with mouse host IDUA antibody (R&D Systems 
MAB-4119) for 2 hours at 1:500 dilution in PBS-Tween solution (0.5% Tween 20 in 1 × PBS) or mouse host 
beta-actin antibody (Sigma) at 1:5000 dilution in PBS-Tween. This was followed by mouse horse radish peroxide 
secondary antibody at 1:10000 dilution in PBS-Tween. Western-Bright Sirius chemi-luminescence reagent was 
used according to product protocol and blots were exposed using autoradiography film.
Cell Transfection comparison of wild-type against codon optimized IDUA. 293 cells were plated onto 
a 24 well plate at 100,000 cells per well. After 24 hours, 3 wells were transfected using a mix of 1ug of plasmid DNA, 
3 μl of PEI and 60 μl of DMEM per well. Total cell protein was harvested after 72 hours by adding 70 μl of Mammalian 
Protein extraction Reagent (Thermo Scientific Cat: 78501), to each well after saving the cell culture supernatant.
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MPS1 Patient Cell Toxicity Assay. Patient Cells were plated onto a 24 well plate at 20,000 cells per well. 
AAV2-opt-IDUA was added after 24 hours in treatments of 5,000 and 50,000 viral genomes per cell with a total of 
eight replicates per treatment. After 72 hours, each well’s supernatant was saved. This was followed by cell resus-
pension using 150 μl of 0.05% trypsin. Trypsin was deactivated by adding back the respective supernatant to each 
well. All samples were analyzed using a Beckman Vi-cell XR cell viability dye exclusion analyzer.
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